Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation involves transferase enzymes that attach chemical moieties such as glucuronic acid, sulfate, methyl, or acetyl groups to drugs, enhancing their elimination. This conjugation process makes drugs more water-soluble, enabling efficient renal or biliary excretion. The major Phase II enzymes include thiopurine S-methyltransferase, UDP-glucuronosyltransferase, and N-acetyltransferase 2, which collectively facilitate drug detoxification and xenobiotic removal.

Genetic polymorphisms in thiopurine S-methyltransferase reduce or eliminate enzyme activity, causing thiopurine drugs like azathioprine and 6-mercaptopurine to accumulate in the body. Patients with TPMT deficiency experience reduced drug metabolism, leading to life-threatening myelosuppression. Genotype-based dose adjustment or alternative therapies are necessary to prevent severe toxicity in affected individuals.

UGT1A1 polymorphisms, particularly the *28 allele, reduce glucuronidation capacity for irinotecan, impairing drug metabolism. The active metabolite SN-38 accumulates to toxic levels, causing dose-limiting toxicities including severe diarrhea and neutropenia. Genotype-guided dosing can mitigate these adverse effects by adjusting irinotecan doses based on individual UGT1A1 genotypes.

NAT2 polymorphisms classify individuals as slow, intermediate, or fast acetylators, affecting isoniazid clearance rates. Slow acetylators experience delayed drug clearance and elevated risk for isoniazid-induced hepatotoxicity due to drug accumulation. Fast acetylators may fail to achieve therapeutic drug concentrations, compromising treatment efficacy. Understanding a patient's NAT2 genotype enables optimized dosing regimens.

Genetic screening for Phase II enzyme polymorphisms enables precision drug therapy by identifying individuals at risk for adverse drug reactions or treatment failure. Understanding pharmacogenetic phenotypes alterations in pharmacokinetics allows clinicians to tailor drug choices and dosages, enhancing safety and improving therapeutic outcomes while minimizing toxicity.

Genetic polymorphisms in Phase II transferase enzymes create marked interindividual variability in enzyme activity, directly influencing drug response and toxicity. These principles of pharmacogenetics types of genetic variants explain why patients metabolize identical drug doses differently. Genetic differences determine whether drugs accumulate to toxic levels or fail to reach therapeutic concentrations.

Conjugation reactions in Phase II metabolism attach polar endogenous groups to drugs, dramatically increasing water solubility and enabling rapid renal or biliary excretion. Unlike Phase I metabolism, which introduces reactive functional groups, Phase II transferase enzymes directly facilitate drug removal. This two-stage process ensures efficient detoxification and prevents drug accumulation in tissues.